Abstract: By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.

Abstract: By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.

Abstract: A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen.

Abstract: A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen.

Abstract: A compound represented by the following formula (I), salt thereof, or hydrate thereof, can effectively relieve itch caused by atopic disease or the like: wherein R represents hydroxyl, C1-6 alkoxy optionally substituted with C1-6 alkoxy, or amino optionally substituted with C1-6 alkyl.

Abstract: A Compound represented by the following general formula (1): wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen or salts thereof or hydrates of the foregoing.

Abstract: A reporter vector which can evaluate the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 and a method for evaluation of the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 by using the reporter vector. A reporter system which can evaluate the ability of a drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 is completed by constructing a reporter vector having a reporter gene linked to the 3? end of a region between CYP1A1 and CYP1A2 or a reporter vector having different reporter genes linked to the both ends of the region, respectively, so as to sandwich the region, and a reporter vector having a deletion mutation in the region, and confirming that the expression of a reporter molecule is increased by the drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 in the reporter system using the reporter vector.

Abstract: A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.

Abstract: A Compound represented by the following general formula (1): wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen or salts thereof or hydrates of the foregoing.

Abstract: A reporter vector which can evaluate the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 and a method for evaluation of the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 by using the reporter vector. A reporter system which can evaluate the ability of a drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 is completed by constructing a reporter vector having a reporter gene linked to the 3? end of a region between CYP1A1 and CYP1A2 or a reporter vector having different reporter genes linked to the both ends of the region, respectively, so as to sandwich the region, and a reporter vector having a deletion mutation in the region, and confirming that the expression of a reporter molecule is increased by the drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 in the reporter system using the reporter vector.

Abstract: A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.

Abstract: A compound represented by the following formula (I), salt thereof, or hydrate thereof, can effectively relieve itch caused by atopic disease or the like: wherein R represents hydroxyl, C1-6 alkoxy optionally substituted with C1-6 alkoxy, or amino optionally substituted with C1-6 alkyl.